A Phase 3b Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of E/C/F/TAF Fixed Dose Combination (FDC) in HIV-1 Infected Subjects on Chronic Hemodialysis
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 13 Oct 2017
At a glance
- Drugs Cobicistat/elvitegravir/emtricitabine/tenofovir alafenamide (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions; Registrational
- Sponsors Gilead Sciences
- 17 Jul 2017 Planned End Date changed from 1 Sep 2018 to 1 Aug 2018.
- 17 Jul 2017 Planned primary completion date changed from 1 Oct 2017 to 1 Sep 2017.
- 10 Jun 2017 Biomarkers information updated